NCT07883070
Study of Anxiety and Depression in Patients With Hematologic Malignancies
At risk: Primary endpoint(s) modified.
See at-risk trials from The First Affiliated Hospital of Xiamen University
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Study title expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
Patients with newly diagnosed lymphoma or multiple myeloma who have a baseline Hospital Anxiety and Depression Scale-Anxiety (HADS-A) score of 8 or higher and/or a Hospital Anxiety and Depression Scale-Depression (HADS-D) score of 8 or higher. All patients receive standard anticancer treatment according to routine clinical practice.
Patients with newly diagnosed lymphoma or multiple myeloma who have baseline HADS-A and HADS-D scores both below 8. All patients receive standard anticancer treatment according to routine clinical practice.
Other: Baseline Anxiety and/or Depression
Sites
1 site in 1 country
- the First Affilaited Hospital of Xiamen UniversityXiamen, Fujian, China